WO1996038571A3 - Recombinant polypeptide cytotoxins for cancer treatment - Google Patents
Recombinant polypeptide cytotoxins for cancer treatment Download PDFInfo
- Publication number
- WO1996038571A3 WO1996038571A3 PCT/US1996/008313 US9608313W WO9638571A3 WO 1996038571 A3 WO1996038571 A3 WO 1996038571A3 US 9608313 W US9608313 W US 9608313W WO 9638571 A3 WO9638571 A3 WO 9638571A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- recombinant polypeptide
- cytotoxins
- cancer treatment
- polypeptide cytotoxins
- cytokine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5403—IL-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Botany (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU59652/96A AU5965296A (en) | 1995-05-31 | 1996-05-31 | Recombinant polypeptide cytotoxins for cancer treatment |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45526395A | 1995-05-31 | 1995-05-31 | |
US08/455,263 | 1995-05-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1996038571A2 WO1996038571A2 (en) | 1996-12-05 |
WO1996038571A3 true WO1996038571A3 (en) | 1997-02-20 |
Family
ID=23808103
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/008313 WO1996038571A2 (en) | 1995-05-31 | 1996-05-31 | Recombinant polypeptide cytotoxins for cancer treatment |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU5965296A (en) |
WO (1) | WO1996038571A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL116436A (en) | 1995-12-18 | 2006-12-31 | Yissum Res Dev Co | Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND |
DE19735105A1 (en) * | 1997-08-13 | 1999-03-04 | Univ Albert Ludwigs Freiburg | New fusion protein |
US6645490B2 (en) | 1998-03-02 | 2003-11-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities |
US6168932B1 (en) | 1998-07-13 | 2001-01-02 | Parker Hughes Institute | Recombinant DTctGMCSF fusion toxin in a baculovirus expression vector system |
CN100497387C (en) | 2001-05-25 | 2009-06-10 | 宾西法尼亚大学托管人 | Chimeric proteins for cell targeting and apoptosis induction and methods of using same |
WO2003087307A2 (en) * | 2002-04-10 | 2003-10-23 | Zymogenetics, Inc. | Use of interleukin-19 to treat cervical cancer |
CA3007075C (en) | 2006-09-07 | 2019-10-15 | Arthur E. Frankel | Methods and compositions based on diphtheria toxin-interleukin-3 conjugates |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992009613A1 (en) * | 1990-12-03 | 1992-06-11 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diphtheria toxin |
WO1993007286A1 (en) * | 1991-09-30 | 1993-04-15 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Recombinant immunotoxins |
WO1993025228A1 (en) * | 1992-06-15 | 1993-12-23 | Whittier Institute For Diabetes And Endocrinology | Cytotoxins specific for gm-csf receptor-bearing cells |
WO1996005865A1 (en) * | 1994-08-22 | 1996-02-29 | Regents Of The University Of Minnesota | Combination immunotoxin/antineoplastic agent therapy for b-lineage cancer |
-
1996
- 1996-05-31 WO PCT/US1996/008313 patent/WO1996038571A2/en active Application Filing
- 1996-05-31 AU AU59652/96A patent/AU5965296A/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992009613A1 (en) * | 1990-12-03 | 1992-06-11 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diphtheria toxin |
WO1993007286A1 (en) * | 1991-09-30 | 1993-04-15 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Recombinant immunotoxins |
WO1993025228A1 (en) * | 1992-06-15 | 1993-12-23 | Whittier Institute For Diabetes And Endocrinology | Cytotoxins specific for gm-csf receptor-bearing cells |
WO1996005865A1 (en) * | 1994-08-22 | 1996-02-29 | Regents Of The University Of Minnesota | Combination immunotoxin/antineoplastic agent therapy for b-lineage cancer |
Non-Patent Citations (13)
Also Published As
Publication number | Publication date |
---|---|
WO1996038571A2 (en) | 1996-12-05 |
AU5965296A (en) | 1996-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU5930396A (en) | Allogeneic cell therapy for cancer following allogeneic stem cell transplantation | |
AU573523B2 (en) | Functional human urokinase proteins | |
AU7327596A (en) | Preparation of phosphorothioate oligomers | |
AU1496288A (en) | Recombinant ricin toxin fragments | |
EP2270047A3 (en) | Anti-C5 antibodies and their therapeutic uses | |
IL124689A0 (en) | Apoptosis induced by monoclonal antibody anti-her2 | |
AU2608292A (en) | Human immunoglobulins produced by recombinant dna techniques | |
EP2336190A3 (en) | Anti-VEGF antibodies | |
EP1200124A4 (en) | Immunoglobulin fusion proteins | |
AU5673596A (en) | Rapid, stable high-titre production of recombinant retroviru s | |
IL132249A0 (en) | Type ii tgf-beta receptor/immunoglobulin constant region fusion proteins | |
ZA200200789B (en) | Multiple cytokine-antibody complexes. | |
EP0871486A4 (en) | Diphtheria toxin epitopes | |
AU7546694A (en) | Monoclonal antibody that induces apoptosis | |
ZA891861B (en) | Monoclonal antibodies | |
WO1996038571A3 (en) | Recombinant polypeptide cytotoxins for cancer treatment | |
WO1997025071A3 (en) | Immunoconjugate for the treatment of aids | |
AU3390995A (en) | Novel implant and novel vector for the treatment of acquired diseases | |
AU5021796A (en) | Recombinant human anti-lewis b antibodies | |
HUP9801438A3 (en) | Recombinant preduodenal lipases and polypeptide derivatives produced by plants, processes for obtaining them and their uses | |
WO1999030736A3 (en) | Methods to treat undesirable immune responses | |
AU542296B2 (en) | Biologically active peptides | |
ATE207757T1 (en) | NOVEL TRIPEPTIDES USABLE FOR IMMUNE AND CNS THERAPY | |
AU6059194A (en) | Monoclonal antibodies to bovine cytokines | |
EP0702725A4 (en) | Method for recombinant production of biologically active polypeptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |